Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Sales (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Return on Sales for 5 consecutive years, with 40.65% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 12734.0% year-over-year to 40.65%, compared with a TTM value of 40.65% through Dec 2025, up 6534.0%, and an annual FY2024 reading of 31.72%, down 1287.0% over the prior year.
  • Return on Sales was 40.65% for Q4 2025 at SAB Biotherapeutics, down from 315.6% in the prior quarter.
  • Across five years, Return on Sales topped out at 315.6% in Q3 2025 and bottomed at 89.62% in Q1 2025.
  • Average Return on Sales over 5 years is 4.44%, with a median of 2.8% recorded in 2022.
  • Peak annual rise in Return on Sales hit 34572bps in 2025, while the deepest fall reached -8430bps in 2025.
  • Year by year, Return on Sales stood at 1.04% in 2021, then crashed by -248bps to 3.63% in 2022, then plummeted by -1963bps to 74.94% in 2023, then dropped by -16bps to 86.69% in 2024, then surged by 147bps to 40.65% in 2025.
  • Business Quant data shows Return on Sales for SABS at 40.65% in Q4 2025, 315.6% in Q3 2025, and 152.04% in Q2 2025.